EGFR-altered lung cancer therapy has emerged as a cornerstone with the use of osimertinib medication, a potent TKI.A major challenge remains with the emergence of drug resistance to this drug.The article analyzes drug resistance mechanisms to osimertinib medication, seeking to uncover the complex aspects behind the phenomenon and offer insights on potential treatment approaches.Several key routes can be categorized in osimertinib medication drug resistance mechanisms, including:The T790M EGFR mutation is one of the key routes in osimertinib medication drug resistance mechanisms.The MET gene amplification is another key pathway in osimertinib…
The care of NSCLC (NSCLC) has been revolutionized by Tagrisso, also known as Tagrisso, which effectively targets the EGFR (EGFR) changes.In managing NSCLC, the emergence of tolerance to Tagrisso presents a significant challenge.Developing effective strategies to overcome Tagrisso tolerance and improve patient success rates is crucial, which requires understanding the basic processes of Tagrisso tolerance.This article will explore the various mechanisms of Tagrisso tolerance, their implications, and potential strategies to address them.A secondary mutation within the EGFR gene, known as T790M mutation, is the most common mechanism of tolerance to…
The care of T790M change-positive NSCLC (NSCLC) has been transformed by the drug, a latest TKI (TKI).However, tolerance to the drug remains a significant challenge in medical use.This article aims to provide a detailed summary of the various tolerance mechanisms associated with the drug in T790M change-positive NSCLC, with a focus on recent advancements and potential strategies for overcoming tolerance.The first mechanism is the epidermal growth factor receptor T790M change and the drug tolerance:In T790M change-positive NSCLC, the epidermal growth factor receptor T790M change is the most common tolerance mechanism…
